The Fox Chase Chemical Diversity Center, Inc. (FCCDC)

 

The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a 2-year Phase I STTR from the National Institute of Arthritis and Infectious Disease Entitled "Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever"

 

Doylestown, PA. May 31, 2018 - FCCDC is pleased to announce that it has been awarded a 2-year Phase I STTR award from the National Institute of Arthritis and Infectious Disease entitled "Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever" (R41AI138630-01), with Prof. Ron Harty, University of Pennsylvania, Principal Investigator.